Search research articles
Contact Us
Filters
Showing results (61-70 of 95) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2001
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties
A W Tolcher, S G Eckhardt, J Kuhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
R F DeVore, D H Johnson, J Crawford, et al.
Cancer Chemotherapy and Pharmacology
|
May 30, 2008
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state
C L O'Bryant, C H Lieu, S Leong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 19, 2007
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors
S Hariharan, D Gustafson, S Holden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
E K Rowinsky, R Humphrey, L A Hammond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 19, 2006
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors
L Gore, S N Holden, R B Cohen, et al.
Cancer Chemotherapy and Pharmacology
|
June 4, 2011
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors
J R Infante, R Kurzrock, J Spratlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2000
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077
C D Britten, E K Rowinsky, S D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
L A Hammond, J R Eckardt, S D Baker, et al.
Oncology (Williston Park, N.Y.)
|
September 3, 1998
Alternative dosing schedules for irinotecan
M L Rothenberg, J G Kuhn, L J Schaaf, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 95) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 2, 2001
Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties
A W Tolcher, S G Eckhardt, J Kuhn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer
R F DeVore, D H Johnson, J Crawford, et al.
Cancer Chemotherapy and Pharmacology
|
May 30, 2008
A dose-ranging study of the pharmacokinetics and pharmacodynamics of the selective apoptotic antineoplastic drug (SAAND), OSI-461, in patients with advanced cancer, in the fasted and fed state
C L O'Bryant, C H Lieu, S Leong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 19, 2007
Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors
S Hariharan, D Gustafson, S Holden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 7, 2000
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies
E K Rowinsky, R Humphrey, L A Hammond, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 19, 2006
A phase I safety, pharmacological and biological study of the farnesyl protein transferase inhibitor, tipifarnib and capecitabine in advanced solid tumors
L Gore, S N Holden, R B Cohen, et al.
Cancer Chemotherapy and Pharmacology
|
June 4, 2011
A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors
J R Infante, R Kurzrock, J Spratlin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 3, 2000
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077
C D Britten, E K Rowinsky, S D Baker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies
L A Hammond, J R Eckardt, S D Baker, et al.
Oncology (Williston Park, N.Y.)
|
September 3, 1998
Alternative dosing schedules for irinotecan
M L Rothenberg, J G Kuhn, L J Schaaf, et al.
Page
of 10